NEW TESTS
Please Note: Not all test codes assigned to each assay are listed in the table of contents.
Please refer to the complete listing on the page numbers indicated.

Test Code	Test Name	Effective Date	Page #
8812	**Cyclosporine A, Trough, Blood**	12/10/2012	2
564	**Haloperidol**	12/10/2012	2
70006	**Tacrolimus and Sirolimus, LC/MS/MS**	12/10/2012	3
26578	**Yellow Dock Weed (RW23) IgE**	12/18/2012	3

TEST CHANGES
Please Note: Not all test codes assigned to each assay are listed in the table of contents.
Please refer to the complete listing on the page numbers indicated.

Test Code	Former Test Code	Test Name	Effective Date	Page #
36721	*4147*	Amiodarone	12/10/2012	6
15220	*4313*	**Cyclosporine, LC/MS/MS, Blood**	12/10/2012	6
416	*S51463*	**Disopyramide**	12/10/2012	6
214	*S51651*	**Ethosuximide**	12/10/2012	7
3081	*S51365*	**Felbamate**	12/10/2012	7
5309	*S51652*	**Flecainide**	12/10/2012	8
22060	*4196*	Lamotrigine	12/10/2012	8
10662	*4910*	Mycophenolic Acid	12/10/2012	9
6278	*S51396*	**Propafenone**	12/10/2012	10
36712	*4940*	**Sirolimus**	12/10/2012	10
70007	*5948*	**Tacrolimus, Highly Sensitive, LC/MS/MS**	12/10/2012	10
37852	*S51653*	**Zonisamide**	12/10/2012	11
5317		**Comprehensive Metabolic Panel**	12/11/2012	11
3351		**Direct LDL**	12/11/2012	12
3522		Folate, Serum	12/11/2012	12
5318		Hepatic Function Panel	12/11/2012	12
1580		Protein Electrophoresis (PEP)	12/11/2012	13
1324		**Protein, Total, Serum**	12/11/2012	13
5319		**Urea Nitrogen (BUN)**	12/11/2012	13
8766		Varicella-zoster Virus IgM Antibodies	12/11/2012	14
8516		Influenza Type A and B Antibodies (IgG,IgM,IgA)	12/18/2012	14
3218		Sex Hormone Binding Globulin (SHBG)	12/18/2012	15

REDIRECTS
Please Note: Not all test codes assigned to each assay are listed in the table of contents.
Please refer to the complete listing on the page numbers indicated.

Test Code	Former Test Code	Test Name	Effective Date	Page #
26474	1413	**Acetylcholine Receptor Modulating Antibody**	12/18/2012	4
18041	*S52456*	**SMA Carrier Screen**	12/18/2012	5

DISCONTINUED TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated.			
Test Code	**Test Name**	**Effective Date**	**Page #**
5924	Actin (Smooth Muscle) Antibody (IgA)	12/11/2012	15
1418	Acetylcholine Receptor Panel	12/18/2012	15
S51931	Allergen - Yellow Dock IgE [71810S]	12/18/2012	15
1026	Myasthenia Gravis Evaluation Plus	12/18/2012	15
7560C	Treponema pallidum Total Antibodies, FTA-Antibodies Quant CSF	12/18/2012	15
3510	Vitamin B12-HoloTC AssessR™	12/18/2012	15

New Test Offerings

The following tests will be available through Quest Diagnostics on the dates indicated below.

Cyclosporine A, Trough, Blood	
Clinical Significance	**Cyclosporine (cyclosporin a) is an immunosuppressant therapeutic agent used in the prevention of organ graft rejection. Measurement of blood levels is recommended due to the inter-individual variability of metabolism as well as the toxicity associated with excessive dosage.**
Effective Date	**12/10/2012**
Test Code	**8812**
CPT Codes	**80158**
Specimen Requirements	**2.0 mL (1.0 mL) Whole Blood EDTA**
Reject Criteria	**Clotted**
Instructions	**Patient Preparation: COLLECT AS A TROUGH 12 HOURS AFTER LAST DOSE.**
Transport Temperature	**Room temperature**
Specimen Stability	**Room temperature: 7 Day** **Refrigerated: 7 Days** **Frozen: 30 Days**
Set-up/Analytic Time	**Sets up: Sun, Mon, Tue-Sat; Report available: 1-2 Days**
Reference Range	**See Laboratory Report**
Units Of Measure	**mcg/L**
Always Message	**No definitive therapeutic or toxic ranges have been established. Optimal blood drug levels are influenced by type of transplant, patient response, time post-transplant, co-administration of other drugs, and drug formulation. The following trough ranges are suggested guidelines:** **Kidney Transplantation: 100-200 mcg/L** **Other Organ Transplant: 200-300 mcg/L**
Methodology	**Immunoassay**
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code: 80031050** — **Result Name: Cyclosporine A, Trough**

Haloperidol	
Clinical Significance	**Monitoring the haloperidol concentration is used to assure compliance and avoid toxicity of this**

	antipsychotic drug.
Effective Date	**12/10/2012**
Former Test Name	*Haloperidol [564]*
Former Test Code	*S51654*
Test Code	**564**
Reject Criteria	Gel barrier/ serum separator tubes
Set-up/Analytic Time	**Set Up: Mon Wed Fri Report available: 3-4 days**
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code** / **Result Name**: **85991660** / **Haloperidol**

Tacrolimus and Sirolimus, LC/MS/MS	
Clinical Significance	**Tacrolimus and Sirolimus are immunosuppressive drugs used in organ transplantation to prevent graft rejection. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity.**
Effective Date	**12/10/2012**
Test Code	**70006**
Specimen Requirements	**4 mL (2 mL) Whole blood EDTA**
Reject Criteria	**Clotted**
Instructions	**Collect specimen 1 hour prior to next dose (12 hour trough)**
Transport Temperature	**Room temperature**
Specimen Stability	**Room temperature: 5 Days** **Refrigerated: 7 Days** **Frozen: 30 Days**
Set-up/Analytic Time	**Set Up: Mon-Sat; Report available: 1-2 days**
Reference Range	**See individual assays**
Units Of Measure	**ng/mL**
Methodology	**LC-MS-MS**
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code** / **Result Name**: **50000320** / **Tacrolimus, LC/MS/MS**; **85990970** / **Sirolimus, LC/MS/MS**

Yellow Dock Weed (RW23) IgE	
Message	Replacement test for discontinued test S51931 Allergen - Yellow Dock IgE [71810S]
Clinical Significance	Yellow dock (*rumex crispus*) is a perennial flowering herb that is native to Europe and now well established throughout the United States as an invasive species. Yellow dock pollen may serve as an aeroallergen in susceptible patients.
Effective Date	**12/18/2012**
Test Code	**26578**
CPT Codes	86003

Specimen Requirements	0.3 mL (0.2 mL) Serum Red-top (no gel) Preferred, SST (Red-top/plastic)
Transport Temperature	Room temperature
Specimen Stability	Room temperature: 14 Days Refrigerated: 14 Days Frozen: 30 Days
Set-up/Analytic Time	Set up: Mon-Sat; Report available: 1-2 Days
Units Of Measure	kU/L
Always Message	**This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.**
Methodology	**Fluorometric Enzyme Immunocapture Assay**
Assay Category	Laboratory Developed Test
Performing Site	Quest Diagnostics Nichols Institute, San Juan Capistrano
CPU Mappings	**Result Code** / **Result Name** 85991869 — Yellow Dock (RW23) IgE 85991870 — Class

Redirects

Acetylcholine Receptor Modulating Antibody	
Clinical Significance	**Myasthenia gravis (MG) is a neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. Modulating Antibody to AChR causes weakness by inhibiting or modulating binding to the receptors.**
Effective Date	**12/18/2012**
Former Test Name	*Acetylcholine Receptor Modulating Autoabs*
Former Test Code	*1413*
Test Code	**26474**
Specimen Requirements	**1 mL (0.3 mL)** Serum
Transport Temperature	**Refrigerated**
Specimen Stability	**Room temperature: 14 Days** Refrigerated: 14 Days **Frozen: 1 Year**
Set-up/Analytic Time	**Set up: Mon, Wed; Report available: 4-8 days**
Reference Range	**<32 % binding inhibition**
Always Message	**This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. Performance characteristics refer to the analytical performance of the test.**
Methodology	Radiobinding Assay
Assay Category	**Laboratory Developed Test**

Performing Site	**Quest Diagnostics Nichols Institute, San Juan Capistrano**
CPU Mappings	**Result Code** / **Result Name**: **85987490** / **Acetylcholine Rec Mod AB**

SMA Carrier Screen	
Effective Date	**12/18/2012**
Former Test Name	*SMA Screen [18041]*
Former Test Code	*S52456*
Test Code	**18041**
Instructions	**Whole blood: Normal phlebotomy procedure. Store and ship ambient immediately. Do not freeze.** **Amniotic Fluid (AF): Collect 10-20 mL of amniotic fluid in 2 sterile plastic containers. See Genetics Specimen Collection (Cytogenetics, Chromosome Studies) Section for detailed specimen instructions.** **Chorionic Villus Sample (CVS): Collect 15-30 mg of chorionic villi in a sterile container. Add 2-3 mL of sterile saline or tissue culture medium.** **Cultured Cells: Ship two 100% confluent T-25 flasks filled with growth media. Ship at room temperature. Do not refrigerate or freeze. Call lab for additional requirements for prenatal testing. Indicate source of cells: Amniotic Fluid (AF) or Chorionic Villus Sample (CVS).** **For prenatal testing please order test code 10262, Maternal Cell Contamination (MCC) Studies with this test. A separate tube of maternal blood (EDTA) must be drawn in order to rule out maternal contamination of the fetal sample.**
Specimen Stability	**Whole Blood:** **Room temperature: 8 Days** Refrigerated: 15 Days **Amniotic fluid, CVS, Cultured Cells:** **Room temperature: 48 hours**
Set-up/Analytic Time	**Set Up: Mon, Weds, Thurs, Sat; Report Avaialable: 4 Days**
Always Message	**This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. Performance characteristics refer to the analytical performance of the test.**
Performing Site	**Quest Diagnostics Nichols Institute, San Juan Capistrano**

CPU Mappings

Result Code:	Result Name:
86008020	Interpretation
86008027	Technical Results
86008021	SMN1
86008026	SMN2
86008023	Comments
86008025	Comments
86008022	Methods
86008024	References

Test Changes

The following test changes will be effective on the dates indicated below. **Please note that only the information that is changing appears in this update.** *Former test names and test codes have been italicized.*

Amiodarone	
Clinical Significance	**Amidarone is an antiarrythmic drug. Therapeutic drug monitoring is useful to monitor compliance and avoid toxicity.**
Effective Date	**12/10/2012**
Former Test Code	*4147*
Test Code	**36721**
Set-up/Analytic Time	Set Up: Tue, Thu, Sat; Report available: **2-4 days**
Reference Range	Amiodarone: **1.5**-2.5 mcg/mL Desethylamiodarone: **1.5**-2.5 mcg/mL
CPU Mappings	**Result Code** / **Result Name** **85991015** / **Amiodarone** **85991016** / **Desethylamiodarone**

Cyclosporine, LC/MS/MS, Blood	
Clinical Significance	**Cyclosporine is a commonly used immunosuppressive drug in patients receiving transplants. LCMSMS methods have higher specificity for the parent compound than Immunoassay. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity. High cyclosporine levels can lead to nephrotoxicity; low levels can lead to organ rejection following transplant. Peak concentrations are reached at around 3.5 hours after oral dosage. Elimination half-life is 10-27 hours.**
Effective Date	**12/10/2012**
Former Test Name	*Cyclosporine A Whole Blood [LC/MS-MS]*
Former Test Code	*4313*
Test Code	**15220**
Specimen Requirements	5 mL Whole blood (2 mL minimum), EDTA (lavender-top) preferred Alternate: Sodium heparin (green-top)
Reject Criteria	**Clotted**
Instructions	**Optimum time to collect sample is 1 hour before next dose. Do not use gel barrier tubes for sample collection.**
Transport Temperature	Refrigerated
Reference Range	**Remove reference range: converted to Always Message.**
Always Message	**No definitive therapeutic or toxic ranges have been established. Optimal blood drug levels are influenced by type of transplant, patient response, time post-transplant, co-administration of other drugs, and drug formulation. The following trough ranges are suggested guidelines:** **Kidney Transplantation: 100-200 mcg/L** **Other Organ Transplant: 200-300 mcg/L**
CPU Mappings	**Result Code** / **Result Name** **85996797** / **Cyclosporine, LCMSMS, Blood**

Disopyramide	
Clinical Significance	**Disopyramide is useful in treating patients with cardiac arrhythmias and tachcardia. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity.**
Effective Date	**12/10/2012**
Former Test Name	*Disopyramide, Serum [416X]*
Former Test Code	*S51463*
Test Code	**416**
Specimen Requirements	1.0 mL (0.5mL) Serum (Red-top, no gel) **Alternates:** **Plasma EDTA** **Sodium Heparin**
Instructions	**Centrifuge and immediately separate serum or plasma specimens from the cells into clean, plastic, screw-capped vial(s). Transport refrigerated (cold packs) (preferred); transport at room temperature is acceptable.**
Transport Temperature	**Room temperature**
Specimen Stability	**Room temperature: 5 Days** **Refrigerated: 14 Days** **Frozen: 35 Days**
Reference Range	**2.0 - 5.0 mg/L**
Methodology	**Immunoassay**
CPU Mappings	**Result Code** / **Result Name** **80015300** / **Disopyramide**

Ethosuximide	
Clinical Significance	**Ethosuximide is an anticonvulsant used to treat seizures. Ethosuximide levels are monitored to assure adequate therapeutic levels are achieved and to avoid toxicity.**
Effective Date	**12/10/2012**
Former Test Name	*Ethosuximide [214X]*
Former Test Code	*S51651*
Test Code	**214**
Instructions	**Collect as a trough just prior to next dose.**
Specimen Stability	**Room temperature: 5 Days** **Refrigerated: 14 Days** **Frozen: 35 Days**
Reference Range	**40-100 mg/L**
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code** / **Result Name** **80015100** / **Ethosuximide**

Felbamate	
Clinical Significance	**Felbamate is an antiepileptic drug used to treat patients with a variety of types of seizures. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity.**

Effective Date	**12/10/2012**
Former Test Name	*Felbamate (Felbatol) [3081X]*
Former Test Code	*S51365*
Test Code	**3081**
Instructions	**Optimum time to collect sample: 1 hour before next dose**
Transport Temperature	**Refrigerated**
Set-up/Analytic Time	**Set Up: Tue Fri: Report available: 4 days**
Reference Range	**Trough 30-50 mcg/mL**
Methodology	**LC-MS-MS**
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code** / **Result Name**: **85988110** / **Felbamate**

Flecainide	
Clinical Significance	**Monitoring the flecainide concentration is used to assure compliance and avoid toxicity of this cardiac drug used to treat ventricular tachcardia and premature contractions.**
Effective Date	**12/10/2012**
Former Test Name	*Flecainide [5309X]*
Former Test Code	*S51652*
Test Code	**5309**
Specimen Requirements	**2.0 mL (0.5 mL)** Serum Red top or Plasma EDTA **Sodium heparin no longer acceptable**
Reject Criteria	Gel barrier tube, **Gross hemolysis, Lipemic sample**
Instructions	**Optimum time to collect sample: 1 hour before next dose**
Set-up/Analytic Time	**Set Up Tue, Thurs; Report available: 2-6 days**
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code** / **Result Name**: **85988120** / **Flecainide**

Lamotrigine	
Clinical Significance	**Lamotrigine is an anticonvulsant drug used as adjunctive treatment for refractory partial seizures.**
Effective Date	**12/10/2012**
Former Test Code	*4196*
Test Code	**22060**
Specimen Requirements	**Plasma ACD is no longer acceptable.**Gel barrier/serum separator tubes, Gross hemolysis, Gross lipemia
Reject Criteria	**Gel barrier/serum separator tubes,** Gross hemolysis, Gross lipemia
Instructions	**Draw 1/2 to 1 hour before next dose at steady-state.** Do not use gel barrier/serum separator tubes.

Specimen Stability	**Room temperature: 48 Hours** **Refrigerated: 5 Days** **Frozen: 14 Days**
Reference Range	**4.0-18.0 mcg/mL**
Methodology	**LC-MS-MS**
CPU Mappings	**Result Code**: **85988150** — **Result Name**: **Lamotrigine**

Mycophenolic Acid	
Clinical Significance	**Mycophenolic acid is an immunosuppressant used in tissue transplants. It prevents graft rejection by the host's immune system. It is very important to monitor it's level. Too little of this drug will cause graft rejection, while too much will lead to infection. Monitoring its level is essential to optimize therapeutic effects, avoid toxicity, and assure compliance.**
Effective Date	**12/10/2012**
Former Test Code	*4910*
Test Code	**10662**
CPT Codes	**83789**
Specimen Requirements	**1 mL (0.5 mL)** Serum in Red-top (no gel) **Alternates:** **1 mL (0.5 mL)** Plasma in EDTA (lavender-top); Sodium heparin (green-top)
Reject Criteria	**Lipemic, Hemolyzed; Improperly labeled; Left at room temperature for more than 72 hours; Specimens collected in gel barrier/serum separator tubes**
Instructions	**Optimum time to collect sample: 0.5 to 1 hour before next dose (trough) at steady-state (3-5 days after treatment with oral doses).** **Serum: Collect blood in plain red-top evacuated tube. Allow blood to clot at 15-28 degrees C for 20-30 minutes. Centrifuge at 20-25 degrees C (2200-2500 rpm, 1000 x g) for 8-10 minutes. Transfer serum to polypropylene or polyethylene transport tube. Ship refrigerated (cold packs). Samples left at room temperature for more than 3 days are not acceptable.** **Plasma: Draw blood into lavender-top evacuated tube. Separate cells by centrifugation at 18-25 degrees C (2500-2800 rpm) for 5-10 minutes. Transfer plasma to polypropylene or polyethylene transport tube. Ship refrigerated (cold packs). Samples left at room temperature for more than 3 days are not acceptable.**
Transport Temperature	Refrigerated
Specimen Stability	**Room Temp: 72 hours** **Refrigerated: 14 days** **Frozen: 14 days**
Set-up/Analytic Time	**Sets up Mon- Sat; Report available: 3 days**
Reference Range	**Mycophenolic Acid: 1.0-3.5 mcg/mL** **MPA Glucuronide: 35.0-100.0 mcg/mL**
Units Of Measure	**mcg/mL**
Methodology	**LC-MS-MS**
Assay Category	Laboratory Developed Test
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**

CPU Mappings	**Result Code** / **Result Name** **86002332** / **Mycophenolic Acid** **86002333** / **MPA Glucuronide**

Propafenone	
Clinical Significance	**Propafenone is a cardiac drug for treating ventricular arrythmias. Therapeutic drug monitoring is important to optimize dose, to assure compliance, and to avoid toxicity.**
Effective Date	**12/10/2012**
Former Test Name	*Propafenone [6278X]*
Former Test Code	*S51396*
Test Code	**6278**
Reject Criteria	**Gel barrier/ serum separator tube**
Instructions	**Collect blood in plain red-top for serum or a sodium heparin (green-top) tube for plasma. Draw sample 2-6 hours post oral dose.**
Transport Temperature	**Room temperature**
Set-up/Analytic Time	**Set Up: Tue, Thurs; Report available: 2-6 days**
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code** / **Result Name** **85988190** / **Propafenone**

Sirolimus	
Clinical Significance	**Sirolimus is an immunosuppresant drug used to prevent organ graft rejection. Therapeutic drug monitoring is used to optimize dose and avoid toxicity. Peak concentrations are reached in 2 hours following oral administration. Elimination half-life in males is approximately 72 hours; in females approximately 61 hours.**
Effective Date	**12/10/2012**
Former Test Name	*Sirolimus MonitR™*
Former Test Code	*4940*
Test Code	**36712**
Specimen Requirements	**2.0 mL (1.0 mL)** Whole Blood EDTA
Reject Criteria	**Clotted**
Instructions	**Collect specimen 1 hour prior to next dose (12 hour TROUGH).**
Transport Temperature	Refrigerated
Set-up/Analytic Time	**Set Up: Mon-Sat; Report Available: 1-2 days**
CPU Mappings	**Result Code** / **Result Name** **85990970** / **Sirolimus, LCMSMS**

Tacrolimus, Highly Sensitive, LC/MS/MS	
Clinical Significance	**Tacrolimus is an immunosuppressive drug which has been shown to be effective for the treatment of rejection following transplantation.**

Effective Date	**12/10/2012**
Former Test Name	*Tacrolimus*
Former Test Code	*5948*
Test Code	**70007**
Specimen Requirements	**2.0 mL (1.0 mL**) Whole Blood EDTA
Reject Criteria	**Clotted**
Instructions	**Collect specimen 1 hour prior to next dose (12 hour trough)**
Transport Temperature	**Room temperature**
Set-up/Analytic Time	**Set Up: Mon-Sat; Report available: 1-2 days**
Reference Range	Trough: 5.0-20.0 ng/mL
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code** / **Result Name**: **50000320** / **Tacrolimus, LC/MS/MS**

Zonisamide	
Clinical Significance	**Zonisamide is comonly used as an adjunct together with other conventional anticonvulsants. As multiple drugs are administered, it is important to monitor its level to optimize therapeutic effects, to assure compliance, and to avoid toxicity.**
Effective Date	**12/10/2012**
Former Test Name	*Zonisamide [37852N]*
Former Test Code	*S51653*
Test Code	**37852**
Instructions	**Collect blood in plain red-top tube.**
Transport Temperature	**Refrigerated**
Specimen Stability	Room Temp: 24 hours Refrigerated: 14 days **Frozen: 45 days**
Set-up/Analytic Time	**Set Up: Mon, Wed, Fri; Report available: 3-4 days**
Performing Site	**Quest Diagnostics Nichols Institute, Valencia**
CPU Mappings	**Result Code** / **Result Name**: **51997374** / **Zonisamide**

Comprehensive Metabolic Panel	
Effective Date	**12/11/2012**
Former Test Name	*Metabolic Panel, Comprehensive*
Test Code	5317
Reference Range	**Globulin:** **Males, g/dL Females, g/dL** **<6 months 1.3-2.4 1.3-2.1** **6-11 months 1.7-3.0 1.2-2.4**

	1-19 years 2.1-3.5 2.0-3.8 **>19 years 1.9-3.7 1.9-3.7** **A/G Ratio: 1.0-2.5 g/dL** **Total Protein:** **Males, g/dL Females, g/dL** **<1 month 4.1-6.3 4.2-6.2** **1-5 months 4.7-6.7 4.4-6.6** **6-11 months 5.5-7.0 5.6-7.9** **1-19 years 6.3-8.2 6.3-8.2** **>19 years 6.1-8.1 6.1-8.1**

Direct LDL	
Effective Date	**12/11/2012**
Former Test Name	*Cholesterol, LDL*
Test Code	3351
Specimen Requirements	**Plasma EDTA no longer acceptable**
Reject Criteria	**Anti-coagulants other than Heparin**
Instructions	**Patient preparation: If an LDL Cholesterol measurement is to be performed along with Triglycerides, the patient should be fasting 9-12 hours prior to collection.**
Specimen Stability	**Room temperature: 5 Days** **Refrigerated: 5 Days** **Frozen: 15 Days**
Reference Range	<20 yrs <110 mg/dL >= 20 yrs <130 mg/dL
Always Message	**Desirable range <100 mg/dL for patient wtih CHD or diabetes and <70 mg/dL for diabetic patient with known heart disease.**
Methodology	Enzymatic

Folate, Serum	
Effective Date	**12/11/2012**
Test Code	3522
Additional Information	**Send serum in an amber tube. If amber tube is not available, wrap tube in aluminum foil to protect from light.**

Hepatic Function Panel	
Effective Date	**12/11/2012**
Test Code	5318
Reference Range	**Added analytes:** **Globulin:** **Males, g/dL Females, g/dL** **<6 months 1.3-2.4 1.3-2.1** **6-11 months 1.7-3.0 1.2-2.4** **1-19 years 2.1-3.5 2.0-3.8** **>19 years 1.9-3.7 1.9-3.7** **A/G Ratio: 1.0-2.5 g/dL** **Change to Total Protein:** **Males, g/dL Females, g/dL** **<1 month 4.1-6.3 4.2-6.2** **1-5 months 4.7-6.7 4.4-6.6** **6-11 months 5.5-7.0 5.6-7.9** **1-19 years 6.3-8.2 6.3-8.2**

	>19 years 6.1-8.1 6.1-8.1
CPU Mappings	**Add components:** **Result Code** / **Result Name** **34557** / **Globulin Total** **34558** / **A/G Ratio**

Protein Electrophoresis (PEP)	
Effective Date	**12/11/2012**
Test Code	1580
Reference Range	**Total Protein:** **Males, g/dL Females, g/dL** **<1 month 4.1-6.3 4.2-6.2** **1-5 months 4.7-6.7 4.4-6.6** **6-11 months 5.5-7.0 5.6-7.9** **1-19 years 6.3-8.2 6.3-8.2** **>19 years 6.1-8.1 6.1-8.1** **A/G Ratio: 1.0-2.5 g/dL**
Tests Affected	**Test Codes:** / **Name:** 1580G / Protein Electrophoresis (PEP) with Scan 1583 / Protein Electrophoresis (PEP) with Monoclonal Region 1583G / Protein Electrophoresis (PEP) with Monoclonal Region with Scan 1584 / Protein Electrophoresis (PEP) Evaluation Serum

Protein, Total, Serum	
Effective Date	**12/11/2012**
Former Test Name	*Protein, Total*
Test Code	1324
Reference Range	Males, g/dL Females, g/dL <1 month 4.1-6.3 4.2-6.2 1-5 months 4.7-6.7 4.4-6.6 6-11 months 5.5-7.0 5.6-7.9 1-19 years 6.3-8.2 6.3-8.2 >19 years 6.1-8.1 6.1-8.1

Urea Nitrogen (BUN)	
Effective Date	**12/11/2012**
Former Test Name	*Urea Nitrogen*
Test Code	5319
Reject Criteria	**Remove** from Notes: Gross hemolyzed samples will be rejected.
CPU Mappings	**Result Code** / **Result Name** **53115** / **Urea Nitrogen (BUN)**

Tests Affected	

Test Codes:	Name:
5315	Metabolic Panel, Basic
5317	Metabolic Panel, Comprehensive
5314	Renal Function Panel

Varicella-zoster Virus IgM Antibodies	
Effective Date	**12/11/2012**
Test Code	8766
Specimen Stability	**Room temperature: 4 Days** **Refrigerated: 7 Days** Frozen: 30 Days

Influenza Type A and B Antibodies (IgG,IgM,IgA)	
Effective Date	**12/18/2012**
Former Test Name	*Influenza Virus A & B IgG, IgM & IgA Antibodies*
Test Code	8516
Specimen Requirements	**Plasma is no longer acceptable.**
Specimen Stability	**Room temperature: 4 Days** **Refrigerated: 7 Days** **Frozen: 30 Days**
Reference Range	**Influenza A IgG:** **Negative <0.9** **Equivocal 0.9 - 1.1** **Positive >1.1** **Influenza A IgM:** **Negative <0.9** **Equivocal 0.9 - 1.1** **Positive >1.1** **Influenza A IgA:** **Negative <0.9** **Equivocal 0.9 - 1.1** **Positive >1.1** **Influenza B IgG:** **Negative <0.9** **Equivocal 0.9 - 1.1** **Positive >1.1** **Influenza B IgM:** **Negative <0.9** **Equivocal 0.9 - 1.1** **Positive >1.1** **Influenza B IgA:** **Negative <0.9** **Equivocal 0.9 - 1.1** **Positive >1.1**
Assay Category	**FDA Exempt**
Tests Affected	

Test Codes:	Name:
8517	Influenza Virus A IgG Abs

	8519	Influenza Virus A IgG & IgM Abs
	8520	Influenza Virus B IgG Abs
	8523	Influenza Virus B IgG & IgM Abs
	8518	Influenza Virus A IgM Abs
	8522	Influenza Virus B IgM Abs

Sex Hormone Binding Globulin (SHBG)	
Clinical Significance	**Testosterone, dihydrotestosterone and estrogens circulate in serum bound to Sex Hormone Binding Globulin (SHBG). SHBG concentrations are increased in pregnancy, hyperthyroidism, cirrhosis, oral estrogen administration and by certain drugs. Concentrations are decreased by testosterone, hypothyroidism, Cushings syndrome, acromegaly and obesity.**
Effective Date	**12/18/2012**
Test Code	3218
Specimen Requirements	1.0 mL (**0.5 m**L) Serum
Reject Criteria	**Plasma; Gross hemolysis**
Additional Information	**Remove collection instructions.**

Discontinued Tests

Actin (Smooth Muscle) Antibody (IgA)	
Effective Date	**12/11/2012**
Test Code	5924
Additional Information	There is no suggested replacement.

Acetylcholine Receptor Panel	
Effective Date	**12/18/2012**
Test Code	1418
Additional Information	Individual components available under test codes 1410 Acetylcholine Receptor Binding Autoantibodies, 1412 Acetylcholine Receptor Blocking Autoantibodies, and 26474 Acetylcholine Receptor Modulating Antibody

Allergen - Yellow Dock IgE [71810S]	
Message	Refer to suggested replacement test 26578 Yellow Dock Week (RW23) IgE in New Offerings section.
Effective Date	**12/18/2012**
Test Code	S51931

Myasthenia Gravis Evaluation Plus	
Effective Date	**12/18/2012**
Test Code	1026
Additional Information	Individual components available under test codes 1410 Acetylcholine Receptor Binding Autoantibodies, 1412 Acetylcholine Receptor Blocking Autoantibodies, 26474 Acetylcholine Receptor Modulating Antibody and 1107 Striational Total Autoantibodies

Treponema pallidum Total Antibodies, FTA-Antibodies Quant CSF	
Effective Date	**12/18/2012**
Test Code	7560C
Additional Information	Recommended replacement test code 2104C, *Treponema pallidum* Total Antibodies [IFA] CSF

Vitamin B12-HoloTC AssessR™	
Effective Date	**12/18/2012**
Test Code	3510
Additional Information	There is no exact replacement for this test. Recommended replacement test code 3504, Vitamin B12, Serum.